Alterity Therapeutics Ltd (NASDAQ: ATHE)

Alterity Therapeutics Limited, known by its ticker symbol ATHE, is a biotechnology company that operates in the field of neurodegenerative diseases treatment development. The company's main business activities encompass the discovery, development, and commercialization of novel therapeutics that target the underlying causes of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease. Alterity Therapeutics conducts its operations in various countries, particularly in Australia and the United States.

The company generates revenue primarily through the development and commercialization of its product candidates. Its primary product candidate is ATH434, a small molecule designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has demonstrated the ability to reduce α-synuclein pathology and preserve nerve cells in preclinical studies.

Alterity Therapeutics holds a leading position within the neurodegenerative diseases treatment industry. Its competitive advantage lies in its lead product candidate, ATH434, which has shown promising results in preclinical studies. The company's technology has been recognized by regulatory agencies, including the US FDA, which has granted orphan drug designation for ATH434 for the treatment of Parkinson's disease. Key competitors within this industry include larger pharmaceutical companies and biotechnology firms that are also developing treatments for neurodegenerative diseases.

Alterity Therapeutics has not disclosed the names of its customers, as its product candidates are still in development. However, the company's product candidates are intended for use by patients suffering from neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and Huntington's disease.

The company's brand names and trade names of its products and services include ATH434, a small molecule designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, and PBT2, a product candidate being developed to treat Alzheimer's disease and Huntington's disease. Additionally, Alterity Therapeutics is developing its technology to combat antimicrobial resistance in superbugs, holding an exclusive worldwide license from UniQuest, the commercialization company of The University of Queensland, for the development and commercialization of novel zinc ionophore technology to combat antimicrobial resistance.

Alterity Therapeutics' discovery platform is robust, enabling the company to identify and develop novel therapeutics for neurodegenerative diseases. The company's discovery platform is based on its expertise in metal-mediated neuroprotection and its ability to design and synthesize novel compounds that target the underlying causes of neurodegenerative diseases. Alterity Therapeutics is currently conducting clinical trials for its product candidates, including ATH434 and PBT2, with clinical trials designed to evaluate the safety, tolerability, and efficacy of its product candidates in patients with neurodegenerative diseases.